Wilson’s disease drugs may be starving a key gut bacterium, study finds

If you or someone you love has Wilson’s disease, a rare inherited disorder that causes toxic copper buildup in the liver and brain, the drugs that control it are lifesaving and non-negotiable. But a new study adds an unexpected wrinkle: those same drugs appear to starve out a beneficial gut bacterium, and the researchers have now shown exactly how and why. The finding does not change treatment advice, but it does add a new piece to the puzzle of why gut and liver problems can persist even when copper levels are under control.

Key Takeaways

• A multi-center study of people with Wilson’s disease found lower levels of the beneficial gut bacterium Akkermansia muciniphila compared to healthy controls, confirmed in a second, independent group of patients.
• Lab experiments showed the two standard Wilson’s disease drugs, zinc acetate and D-penicillamine, both suppress this bacterium’s growth by stripping the copper it needs to survive, not through a generic antibiotic effect.
• The drugs also disrupted the bacterium’s gene expression, especially genes involved in handling metal ions, hinting at a broader metabolic disruption beyond copper toxicity itself.
• The study does not show that losing this bacterium worsens Wilson’s disease, and researchers caution the cohorts were small and diet and body weight also shaped the results.

Wilson’s disease drugs suppress the gut bacterium Akkermansia muciniphila

Researchers publishing in iScience report that patients with Wilson’s disease (WD), caused by mutations in the gene ATP7B (which makes a protein that moves copper out of cells), have measurably lower gut levels of Akkermansia muciniphila, a bacterium that lives in the gut’s mucus layer and is a bacterium already tied to liver and metabolic health in other conditions. When the team grew this bacterium in the lab and exposed it to the two drugs most commonly prescribed for WD, both drugs stopped it from growing normally, and the researchers traced the cause to a specific mechanism: copper starvation, not a generic antimicrobial effect.

Why Wilson’s disease patients and gut-liver axis researchers should care

Wilson’s disease is rare, but the mechanism it exposes is not. The disorder causes copper to accumulate mainly in the liver and brain, producing hepatic, neurological, and psychiatric symptoms, and prior research has already tied liver injury more broadly to gut microbiota disruptions via the gut-liver axis (the two-way biochemical communication between intestinal bacteria and the liver). If a bacterium known elsewhere for reducing liver inflammation and improving insulin sensitivity is being suppressed as a side effect of standard treatment, that raises the question of whether WD patients are missing out on a protective microbe precisely when their livers need the most help. For readers managing other liver-related or metabolic conditions, the study is also a reminder that some drugs can reshape the gut microbiome through mechanisms that have nothing to do with their intended target.

A multiomics, multi-center study with independent validation

The team combined three data layers in an in-depth phenotyped, multi-center patient cohort: blood metabolite profiling by NMR spectroscopy, lipid profiling by mass spectrometry, and gut bacterial profiling by sequencing the 16S rRNA gene (a standard method for identifying bacterial species from a stool sample) in patients’ feces. Out of more than 3,000 bacterial groups detected, about 40 differed significantly between WD patients and controls after adjusting for sex, age, and body mass index (BMI). Akkermansia muciniphila and five other groups, including Eubacterium ruminantium, Christensenella, Coprococcus, Klebsiella, and Dialister, were reduced in WD patients, while five other groups, including Prevotella and Ligilactobacillus (formerly known as Lactobacillus), were more abundant. Because a correlation in patients cannot prove the drugs caused the bacterial changes, the researchers moved to the lab: they cultured Akkermansia muciniphila with the two WD drugs at doses meant to mimic real prescriptions, D-penicillamine (Cupripen) and zinc acetate (Wilzin). Zinc acetate completely blocked the bacterium’s growth. D-penicillamine tripled its normal doubling time, delaying growth by 5.7 hours. When the researchers added copper back to the D-penicillamine cultures, growth returned to nearly normal, confirming the drug was working by depriving the bacterium of copper rather than by acting as an antibiotic. Gene-expression analysis of the treated bacteria also found roughly 30 genes altered, most of them tied to metal-ion transport and metabolism, consistent with a copper-starvation response.

What this could mean if you or a family member has Wilson’s disease

This is not a reason to stop or change WD medication; copper accumulation in the liver and brain is dangerous, and both zinc acetate and D-penicillamine remain the evidence-based standard of care. What the study does suggest is a plausible, and testable, explanation for why gut and metabolic symptoms can linger in treated patients, and a rationale for future research into whether restoring Akkermansia muciniphila, through diet, prebiotics, or a probiotic supplement, could help alongside standard treatment. That idea is not yet proven in Wilson’s disease and should not be attempted as self-treatment; the first human trial of oral Akkermansia supplementation in an unrelated population (obesity and insulin resistance) only appeared in 2019, and its relevance to WD has not been tested. Anyone with WD who has ongoing digestive symptoms should raise them with their treating physician rather than pursue supplements independently.

What the study cannot yet tell us

The human validation groups were small, 11 patients for the metabolite-based classification model and 10 for confirming the drop in Akkermansia muciniphila by a separate lab method (quantitative PCR), so the findings need replication in larger cohorts before they can be considered settled. The researchers also found that sex and BMI independently shaped gut bacterial composition, as did diet, since WD patients in the study reported eating more sugar, dairy, and alcohol and less fiber than controls, likely reflecting dietary counseling given after diagnosis. That means some of the bacterial differences between WD patients and controls in the human data cannot be cleanly separated from these other factors. Most importantly, the study does not establish whether losing Akkermansia muciniphila actually makes Wilson’s disease worse, or whether it is simply a side effect of necessary treatment with no measurable downside for patients.

What comes next for gut-liver axis research in Wilson’s disease

The authors frame their findings as a case for treating the gut microbiome as a relevant variable in WD care, rather than an afterthought to copper metabolism. The logical next step would be a clinical trial testing whether a microbiome-focused intervention, alongside standard chelation or zinc therapy, changes liver outcomes or symptoms in WD patients, but no such trial has been announced. Larger, longer-running cohorts that separate diet and body-weight effects from drug effects would also help settle how much of the microbiome shift is really about the medication versus the disease itself.

Common Questions

What is Wilson’s disease?
It is a rare inherited disorder caused by mutations in the ATP7B gene that prevent the body from properly removing excess copper, leading to toxic copper buildup mainly in the liver and brain.

What is Akkermansia muciniphila and why does it matter here?
It is a bacterium that lives in the gut’s protective mucus layer and has been linked in other studies to better liver health, insulin sensitivity, and lower inflammation; this study found it depleted in Wilson’s disease patients and traced that depletion to the disease’s standard drugs.

Should people with Wilson’s disease stop taking zinc acetate or D-penicillamine because of this study?
No. Both drugs remain the standard, life-protecting treatment for controlling copper toxicity; this study does not show any harm from continuing them, only a gut-bacterial side effect whose clinical significance is still unknown.

Could a probiotic restore the missing bacteria?
That has not been tested in Wilson’s disease patients specifically; oral Akkermansia muciniphila supplements have been trialed in other conditions like obesity, but anyone with WD should discuss any supplement with their treating physician rather than self-prescribe.

References

Edna Ripollés-Campos, Paula Hernández-Calderón, Martina Palomino-Schätzlein, et al. (2026). Integrated multiomics analysis reveals metabolic and microbiome alterations in Wilson disease. iScience. https://doi.org/10.1016/j.isci.2026.117101